Annexon, Inc. (ANNX)
NMS · Healthcare · Biotechnology
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (57.0M) | (50.3M) | (46.1M) | (57.2M) |
| Net Income | (54.9M) | (48.3M) | (44.1M) | (55.3M) |
| Diluted EPS | $-0.37 | $-0.28 | $-0.23 | $-0.28 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (145.6M) | (143.7M) | (154.1M) | (216.4M) |
| Net Income | (141.9M) | (134.2M) | (138.2M) | (206.7M) |
| Diluted EPS | $-2.60 | $-1.77 | $-1.01 | N/A |